Abstract: A new glycoprotein is characterized by a protein consisting essentially of 75.+-.6% of .alpha.-amino-acids, a carbohydrate portion of 24.6.+-.5.2%, which contains 8.9.+-.2% of hexoses, 7.1.+-.1.5 of N-acetylated hexosamine, 0.2.+-.0.2% of fucose, 8.4.+-.1.5% of, N-acetylated neuraminic acid; a sedimentation coefficient S.sub.20w of 2.5.+-.0.3 S; a molecular weight of 35,000.+-.5,000, determined in the ultracentrifuge, and a molecular weight of 65,000.+-.10,000, determined in polyacrylamide gel containing sodium dodecyl sulfate; an iso-electric point at pH 3.4.+-.0.4; an extinction coefficient E.sub.1.sup.1%.sub.cm (280 nm) of 1.9.+-.0.3; an electrophoretic mobility in the range between that of .alpha..sub.1 and .alpha..sub.2 -globulins; and a specific immunologic reaction with an antibody specifically directed against the glycoprotein.

Abstract: The invention relates to a tissue specific protein, i.e. a substance which is a constituent of parenchymatous tissues, and to a process for preparing the same. The tissue protein is characterized by a protein proportion of 94.+-.3%, essentially consisting of .alpha.-amino acids,an amino acid analysis of______________________________________ Variation Mol % coefficient (%) ______________________________________ lysine 5,64 12.7 histidine 1.05 15.0 arginine 3.83 9.2 aspartic acid 9.84 6.8 threonine 4.33 15.7 serine 4.78 8.2 glutamic acid 11.29 3.5 proline 6.41 9.2 glycine 8.65 9.8 alanine 7.51 6.4 cystine/2 2.11 12.6 valine 6.68 7.9 methionine 0.98 14.5 isoleucine 3.32 7.4 leucine 14.43 4.2 tyrosine 5.10 14.9 phenylalanine 3.08 13.5 and tryptophan 1.14 11.4 ______________________________________a carbohydrate proportion of 5.4.+-.2.2% consisting of 3.0.+-.1% of hexoses, 1.2.+-.0.5% of hexosamine, 0.2.+-.0.2% of fucose, and 1.0.+-.0.5% of neuraminic acid,a sedimentation coefficient S.sub.20,w.sup.c=0.1 of 3.5 S.

Abstract: What is disclosed is a glycoprotein having proteolytic, fibrinolytic, and thrombolytic properties and which can be used to prepare anti-sera useful as diagnostic agents, said glycoprotein being found in human blood serum and extracts of human placentas and being capable of isolation therefrom and which has the following properties:a protein proportion essentially consisting of 89.+-.4% of .alpha.-amino-acids,a carbohydrate proportion of 11.1.+-.2.2%, among it 5.3.+-.1.1% of hexoses, 2.8.+-.0.5 N of N-acetylated hexosamine, 2.9.+-.0.6% of N-acetylated neuraminic acid;a sedimentation coefficient S.sub.20x of 3.2.+-.0.3 S;a molecular weight of 32 000.+-.6 000;an iso-electric point at pH 4.3.+-.0.3;an extinction coefficient E.sub.1 cm.sup.1% (280 nm) of 13.8.+-.1.0;an electrophoretic mobility in the range between that of albumin and .alpha..sub.1 -globulins;a specific immunologic reaction with an antibody specifically directed against the protein, anda proteolytic activity, as well as a process for isolating it.

Abstract: A pregnancy-specific .beta..sub.1 -glycoprotein, characterized by an electrophoretic migration speed in agar gel in the range of the .beta..sub.1 -globulins, a sedimentation constant of 4.6 S.+-.0.5 S, a molecular weight of 100 000.+-.15 000, an extinction coefficient E.sub.1cm.sup.1% of 11.6.+-.0.5 (278 m.mu.; 1/15-molar phosphate buffer, pH 7.0), a carbohydrate content of 28.05.+-.1.55%, comprising 10.7.+-.1.0% of hexoses, 10.0.+-.0.5% of hexosamine, 0.55.+-.0.05% of fucose and 7.0.+-.0.5% of neuraminic acid, and process for isolating it from the placenta or blood or urine of pregnant women. This protein may be used as a reagent and for the preparation of antisera as reagents for the detection of pregnancy and for pre-natal supervision.

Abstract: A pregnancy-specific .beta..sub.1 -glycoprotein, characterized byAn electrophoretic migration speed in agar gel in the range of the .beta..sub.1 -globulins,A sedimentation constant of 4.6 S .+-. 0.5 S,a molecular weight of 100 000 .+-. 15 000,An extinction coefficient E.sub.1cm.sup.1% of 11.6 .+-. 0.5 (278 m.mu.; 1/15-molar phosphate buffer, pH 7.0),a carbohydrate content of 28.05 .+-. 1.55%, comprising 10.7 .+-. 1.0% of hexoses, 10.0 .+-. 0.5% of hexosamine, 0.55 .+-. 0.05% of fucose and 7.0 .+-. 0.5% of neuraminic acid,And process for isolating it from the placenta or blood or urine of pregnant women. This protein may be used as a reagent and for the preparation of antisera as reagents for the detection of pregnancy and for pre-natal supervision.

Abstract: The invention relates to two new glycoproteins called AP-glycoproteins, in particular the .beta..sub.1 -AP-glycoprotein which is characterized by an electrophoretic migration speed in agar gel in the range of that of the .beta..sub.1 -globulins and a molecular weight of about 100,00 (.+-. 10%) and the alpha.sub.2 -AP-glycprotein which is characterized by an electrophoretic migration speed in agar gel in the range of that of the alpha.sub.2 - glycoproteins and a molecular weight of about 300,000 (.+-. 10%), as well as to their use as reagents and for the preparation of anti-serums.

Abstract: A derivative of the steroid-binding .beta.-globulin which can be obtained therefrom by treatment with neuraminidase.

Abstract: Use of the pregnancy-specific .beta..sub.1 -glycoprotein (SP.sub.1) and its antibody for contraception and for inducing miscarriages.

Abstract: A process for isolating a fibrin-stabilizing factor, factor XIII, by extracting human placentae with sodium chloride solution; adding diamino-ethoxy-acridine lactate (DEAL); recovering the resultant precipitate and dissolving it in dilute alkali metal chloride solution containing a complexing agent; adding a quaternary ammonium base to the solution to precipitate inactive materials; reprecipitating the active principal from solution with DEAL; again dissolving the precipitate in dilute alkali metal chloride solution containing a complexing agent; reprecipitating the active principal by adding solid ammonium sulfate; forming a paste between the precipitate and a dilute solution of a complexing agent; dialyzing the paste; gel filtering the dialyzed product; precipitating the active principal from the active fractions with ammonium sulfate; dissolving the precipitate in a neutral tris-(hydroxymethyl)-aminomethane hydrochoric acid buffer containing a complexing agent; dialyzing the solution; and precipitating the